Dwight Moxie - Feb 2, 2022 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Signature
/s/ Dwight Moxie
Stock symbol
RVNC
Transactions as of
Feb 2, 2022
Transactions value $
-$739,338
Form type
4
Date filed
5/16/2023, 08:29 PM
Previous filing
Sep 28, 2021
Next filing
Mar 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Award $0 +42.3K +87.83% $0.00 90.6K Feb 2, 2022 Direct F1
transaction RVNC Common Stock Sale -$739K -21.4K -23.63% $34.55 69.2K May 15, 2023 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents settlement of a performance-based restricted stock unit ("PSU") granted on February 2, 2022. On May 12, 2023, the Issuer's Compensation Committee certified 100% of the PSUs eligible to vest based on pre-established criteria related to the price of the Issuer's common stock.
F2 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F3 The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.02 to $34.55. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.